Discover
etrasimod (APD334) / ArenaEtrasimod: Completion of enrollment of P3 ELEVATE UC 52 trial (NCT03945188) for ulcerative colitis in Q4 2020 (Arena) - Sep 24, 2020 - Jefferies Virtual Next Generation IBD Therapeutics Summit: Top-line data from P3 ELEVATE UC 52 trial for ulcerative colitis in Q4 2021; Top-line data from P3 ELEVATE UC 12 trial (NCT03996369) for ulcerative colitis in Q4 2021 [Screenshot]Jyseleca (filgotinib) / GileadStock market look: Galapagos on track in Japan and EU [Google Translation] (DeAandeelhouder.nl) - Sep 24, 2020 - "The filing for ulcerative colitis in the United States will depend on the results the Manta study produces in the first half of 2021...The Phase 3 Diversity study of filgotinib with Crohn's disease is expected to provide data in 2022."etrasimod (APD334) / ArenaEtrasimod: Initiation of trial for ulcerative colitis in early 2021 (Arena) - Sep 24, 2020 - Jefferies Virtual Next Generation IBD Therapeutics Summit [Screenshot] Entyvio (vedolizumab) / TakedaCHRONOS: A Study to Observe the Safety and Efficacy of Vedolizumab in Biologically Naive Participants With Ulcerative Colitis (UC) or Crohn´s Disease (CD) (clinicaltrials.gov) - Sep 25, 2020 - P=N/A; N=60; Completed; Sponsor: Takeda; Active, not recruiting --> Completed; N=150 --> 60ABX464 / AbivaxAbivax Presents First-Half 2020 Financial Results and Operations Update (Yahoo Finance) - Sep 26, 2020 - "77% (180/232) of patients randomized in ABX464 Phase 2b ulcerative colitis study, recruitment expected to be completed by the end of 2020. ABX464 pivotal Phase 2b/3 trial for Crohn's disease planned with anticipated start of patient recruitment in Q1 2021...."
